NuPathe

Pharma

Migraine patch application resubmitted for FDA approval

NuPathe (NASDAQ:PATH), a biopharmaceutical company, has resubmitted a new drug application for its migraine patch to the U.S. Food and Drug Administration  after resolving issues raised in a complete response letter last year. The Zelrix transdermal patch is designed to transmit sumatriptan via electrical charge through the skin in a drug-delivery method known as iontophoresis. […]

News

NuPathe to resubmit migraine patch for approval in 2012

NuPathe (NASDAQ: PATH) said it will resubmit a new drug  application for its transdermal migraine patch for approval by the U.S. Food and Drug Administration after receiving a complete response letter from the regulator, according to the company’s third quarter earnings report. NuPathe said the issues raised in the August 29 letter from the FDA […]

presented by
News

Return of the public option? Don’t bet on it (Morning Read)

Highlights of the important and the interesting from the world of healthcare: Return of the public option? Don’t bet on it: Nearly 130 House Democrats are pushing to restore the  once-proposed “public option“–essentially a government-run health plan. Fueling  the drive is a report from the Congressional Budget Office that said a public option would shave […]